%0 Journal Article
%K Canada/epidemiology
%K Cohort Studies
%K *Diabetes Mellitus, Type 2/drug therapy/epidemiology
%K *Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
%K Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/therapeutic use
%K Glucagon-Like Peptide 1
%K Glucagon-Like Peptide-1 Receptor/agonists
%K Glucose
%K Humans
%K Hypoglycemic Agents/pharmacology/therapeutic use
%K Sodium
%K *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
%K *Symporters/therapeutic use
%K United Kingdom/epidemiology
%K Type 2 diabetes
%K dipeptidyl peptidase 4 inhibitors
%K glucagon-like peptide 1 receptor agonists
%K sodium-glucose co-transporter 2 inhibitors
%K not involving SGLT-2 inhibitors or DPP-4 inhibitors.
%B BMC Endocr Disord
%D 2022
%G eng
%M 36175881
%P 241
%R 10.1186/s12902-022-01140-1
%T Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom
%V 22
%2 PMC9520836
%7 2022/09/30
%@ 1472-6823